ChemoCentryx (NASDAQ:CCXI) will be announcing its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. The company had revenue of $15.02 million during the quarter, compared to the consensus estimate of $16.88 million. ChemoCentryx had a net margin of 18.69% and a return on equity of 39.31%. On average, analysts expect ChemoCentryx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
CCXI stock opened at $11.54 on Wednesday. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $580.07 million, a price-to-earnings ratio of 33.91 and a beta of 1.78. ChemoCentryx has a 12 month low of $5.42 and a 12 month high of $15.08.
In other news, insider Plc Glaxosmithkline sold 7,343,492 shares of the business’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $11.69, for a total value of $85,845,421.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Markus J. Cappel sold 30,237 shares of the business’s stock in a transaction on Friday, October 26th. The stock was sold at an average price of $11.01, for a total transaction of $332,909.37. Following the completion of the sale, the insider now owns 54,063 shares of the company’s stock, valued at $595,233.63. The disclosure for this sale can be found here. 14.50% of the stock is currently owned by insiders.
An institutional investor recently raised its position in ChemoCentryx stock. Bank of New York Mellon Corp lifted its position in ChemoCentryx Inc (NASDAQ:CCXI) by 11.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 118,778 shares of the biopharmaceutical company’s stock after buying an additional 12,158 shares during the quarter. Bank of New York Mellon Corp owned about 0.24% of ChemoCentryx worth $1,565,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 53.18% of the company’s stock.
Several analysts have commented on CCXI shares. BidaskClub raised shares of ChemoCentryx from a “hold” rating to a “buy” rating in a research report on Thursday, August 30th. ValuEngine raised shares of ChemoCentryx from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. B. Riley started coverage on shares of ChemoCentryx in a research report on Friday, September 7th. They issued a “neutral” rating and a $12.50 target price for the company. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “strong-buy” rating and set a $16.00 target price for the company in a research report on Tuesday, July 10th. Finally, JPMorgan Chase & Co. downgraded shares of ChemoCentryx from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $14.00 to $15.00 in a research report on Tuesday, August 14th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $16.58.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/chemocentryx-ccxi-set-to-announce-earnings-on-thursday.html.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Featured Story: What is insider trading?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.